Deucravacitinib by Bristol-Myers Squibb can help with psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and systemic lupus erythematosus.
AbbVie
Posted inNew Drugs, Oncology, Rare/Orphan Diseases, Regulatory
Tecvayli: New Drug for Multiple Myeloma
Teclistamab by Johnson & Johnson is a new hope for refractory or relapsing multiple myeloma.
Posted inNew Drugs, Regulatory
Vuity: First Pharmacological Treatment for Presbyopia
Pilocarpine by Allergan and AbbVie is the first drug for age-related farsightedness.
Posted inClinical Trials, In the Pipeline, Neuroscience
Treating Parkinson’s Disease: Betting on Alpha-Synuclein
The pharmaceutical industry continues to fight hard against the devastating neurodegenerative disease.
Posted inAutoimmune Diseases, New Drugs, Regulatory
Zeposia: New Drug for Ulcerative Colitis
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Posted inNeuroscience, New Drugs, Regulatory
Reyvow: Completely New Drug for Acute Treatment of Migraine
In the task of getting rid of headaches lasmiditan by Eli Lilly is as effective as the popular triptans, but safer.
Posted inOncology, Research
Not All Cancer Drugs Are Equally Useful
Cheating out of ignorance, or Sleight of hand and no fraud. How pharmaceutical companies scam clinical trials.
